Literature DB >> 33016782

Novel compound heterozygous mutations of PCNT gene in MOPD type II with central precocious puberty.

Yaping Ma1, Zhuangjian Xu1, Jinling Zhao1, Handan Shen1.   

Abstract

We report on a 6-year and 11-month old girl with short stature, microcephaly, proboscis nose, small teeth, left breast Tanner stage II, and nasopharynx adenoid hypertrophy. Her gestational age was 37 weeks and birth weight was 800 g. Her growth hormone peak was higher than 35.2 ng/ml, luteinizing hormone peak 8.97 IU/l, and blood glucose of 120 min 7.82 mmol/l in oral glucose tolerance test. Genetic testing revealed two novel heterozygous mutations in the PCNT gene, an insertion mutation at c.1828dupT (p.S610Ffs*32), and a splice site mutation at c.1207 + 1G>A, which were inherited from healthy carrier patients. This case shows that MOPDII can be associated with central precocious puberty and impaired glucose tolerance in addition to intrauterine growth restriction, postpartum growth defect, and microcephaly.

Entities:  

Keywords:  PCNT gene mutation; Microcephalic Osteodysplastic Primordial Dwarfism Type II; abnormal glucose tolerance; adenoid hypertrophy; central precocious puberty

Year:  2020        PMID: 33016782     DOI: 10.1080/09513590.2020.1827382

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  2 in total

1.  Novel frameshift variant in the PCNT gene associated with Microcephalic Osteodysplastic Primordial Dwarfism (MOPD) Type II and small kidneys.

Authors:  D Hettiarachchi; S M V Subasinghe; G G Anandagoda; Hetalkumar Panchal; P S Lai; V H W Dissanayake
Journal:  BMC Med Genomics       Date:  2022-04-14       Impact factor: 3.063

2.  A novel homozygous mutation of the PCNT gene in a Chinese patient with microcephalic osteodysplastic primordial dwarfism type II.

Authors:  Haifeng Liu; Na Tao; Yan Wang; Yang Yang; Xiaoli He; Yu Zhang; Yuantao Zhou; Xiaoning Liu; Xingxing Feng; Meiyuan Sun; Fang Xu; Yanfang Su; Li Li
Journal:  Mol Genet Genomic Med       Date:  2021-07-31       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.